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The global legal cannabis market is divided into three segments (Recreational, Medical, and 
Industrial), and is expected to have a combined 25% CAGR and reach the $USD 100Bn 
valuation by 2025, driven by the consolidation of American and European markets.  
Aurora is a major player and has been supporting its growth with acquisitions financed by 
equity issuances, putting some pressure on its financial performance. 
Nevertheless, if legalizations follow the expected pace, and if Aurora manages to build solid 
partnerships in markets where it has lower influence (e.g. US), the quality of its products and 
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Summary 
▪ The global legal cannabis market is divided into three 
major segments (recreational and medical marijuana, and 
industrial hemp) and is expected to have a combined 25% CAGR 
(further details in the report) over the next years and reach the 
$USD 100Bn valuation by 2025, mostly driven by the consolidation 
of American and European recreational markets.  
▪ Aurora Cannabis is a top-three player in the industry, being 
the largest producer in the world. This position is the result of an 
intensive M&A strategy (over USD$ 3Bn in the last two years), 
allowing the firm to be present in all geographies with solid 
contracts in countries with strict regulations (e.g. Aurora is one of 
the only firms to have licenses to produce and sell in Europe). This 
might reveal itself as important since the industry is expected to 
consolidate into the largest players over the next years due to high 
regulatory impositions on production and distribution (similar to the 
tobacco industry).  
▪ Main risks relate to the fact that in a fast-growing industry 
with no cash flow generation and where constant investments are 
required, the lack of a financial or strategic partner (main 
competitors already have) and the low access to debt markets 
force the firm to finance its growth with equity issuances. This 
represents bad signaling for investors, who do not like recurrent 
issuances due to the dilution it causes. 
▪ This causes pressure for the company to start presenting 
positive results (EBITDA expected to be positive until 2024), and 
the need for an urgent strategy to capture market share in the US 
(the world’s biggest market), in line with what competitors have 
been doing. Also, the pace of legalizations in Europe will be 
important for the company, since it is a market where the company 
is targeting a strong strategic position. 
 
 AURORA CANNABIS COMPANY REPORT  
 HEALTHCARE 4 JANUARY 2020  
    
Recommendation: BUY 
  
Price Target Mar-21: CAD 6.75$ 
  
Price (as of 3-Jan-20) CAD  2.79$ 
Source: Bloomberg 
  
52-week range ($ CAD) 2.82-13.67 
Market Cap ($Bn CAD) 4.205 









(Values in $M CAD) 2018 2019E 2020F 
Revenues 55.2 281.1 669.2 
EBITDA (90.3) (253.2) (413.1) 
Net Profit (57.9) (337.1) (647.2) 
Unlevered Cash Flow (1,483) (3,402) (2,277) 
EPS (0.16) (0.29) (0.51) 
P/E n/a n/a n/a 





Aurora Cannabis was founded in Canada in 2011 and 
is a leading player in the industry, present in the 
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The Cannabis Sector 
Overview 
The sector can be split into three main segments (Recreational, Medical and 
Industrial), each of these with its specific characteristics, clients, channels, or even 
products.  
The recreational segment has always existed and is benefiting from a recent wave 
of legalizations among countries. The medical sector (where Aurora started to 
position itself) has been under the radar in recent years, due to main research and 
case studies that have been revealing good results for the treatment of diseases 
(such as Parkinson, Multiple Sclerosis, Spinal Cord Disease, Arthritis, Epilepsy, 
Insomnia, among others) with the use of cannabis. The industrial sector uses 
hemp1  and is focused on producing different cannabis-derivative products (e.g. 
rope, textiles, clothing, food, paper, bioplastics, insulation, biofuel, among others). 
 
 
As shown in Figure 1, the cannabis global market was over $USD 100Bn in 2018. 
This value comes almost in its entire amount from the illegal recreational market 
that exists, and is perfectly consolidated, in the majority of countries running in 
parallel economy. With the surge in legalizations for recreational use, the increase 
in medical uses2, and the rise in industrial hemp products due to its lower price, 
the size of the overall market (both legal plus illegal3) is expected to surpass the 
 
1 Derivation of the cannabis plant which is different from marijuana 
2 Several products were already approved by the state organizations and are already part of the national health systems 
subsidized by the state (e.g. in Portugal “Sativex” was the first product to be subsidized by the health system), and 
doctors are allowed to prescribe the drug. These products will compete directly with already-existent drugs specifically 
for Parkinson and Multiple Sclerosis. 
3 The illegal market was measured by aggregating data from the reports mentioned as well as opinions from an 
“opposite” interest lobby in order to have a more robust sizing. 
“Cannabis Global Market was 
over $USD 100Bn in 2018. This 
value comes almost in its 
entire amount from the illegal 
recreational market” 
 
“The Sector can be split into 
three main segments: 
Recreational, Medical and 
Industrial” 
Figure 1: Global Cannabis Market 2019-2025; Sources:Aphria Annual Report; Prohibition 
Partners; Global Cannabis Report; New Frontier Data; Euromonitor; UN ODC 
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$USD 150Bn by 2025 (5% CAGR), where the major driver is the conversion of the 
illegal recreational segment into legal. 
In terms of the supply chain, the recreational market is more fragmented, having 
several small players especially because no major firm wanted to bear the 
reputational risk of entering the market and failing. Major markets4 are mostly in 
North America (approximately 1/3 of the total global market) and Europe, with 
variations depending on each sector (Figure 2). 
 
Figure 2: Cannabis Legal Market ($USD) - Medical & Recreational; Source: Euromonitor 
Products available already show a comprehensive variety of options (Figure 3). In 
the industrial segment, hemp products will be used for industrial purposes (e.g. 
textiles, clothing, paper, among others). When it comes to marijuana products, 
both medical and recreational products can exist in similar forms, except for tablet 
pills made with cannabis (which represent less than 1% of the market). The 
remaining products are the dried flower and prerolls (more than 50% of the offer), 
the vaporizers (have been gaining share over the years because they are seen as 
less harmful and already represent around 30% of the offer), and the so-called 
Cannabis 2.0 products (representing the new wave of products in form of edibles 
such as chocolates or cookies that already represent around 15% of the market 
and are expected to grow over the next years). 
In terms of production and product characteristics, there are no relevant 
differences between different companies, and therefore the brand value and its 
selling power are crucial for the success of the companies. Nevertheless, it is 
important to understand the differences between cultivation, transformation, and 
distribution, and whether the companies position themselves in each of them, or if 
they integrate the three of them (which is the most common with both Aurora and 
its main competitors). 
 














“In the US the average 
consumer in the recreational 
segment is thirty-seven years 
old and married with children” 
“Can the same weed be legal 
and considered medical when 
prescribed by a doctor, and at 
the same time be illegal when 
someone buys it on the streets 
to have fun with friends?” 
Figure 3: Sales by product; Source: 
Deloitte “Cannabis 2.0” Report 
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When referring to the production conditions, although cannabis is a plant that tends 
to generate better output when produced among the tropics, it is good in adapting 
to other conditions and has also shown good results in indoor farming. Therefore, 
the choice of locations is more dependent on strategic decisions such as proximity 
to the distribution network or legal barriers on importation, rather than on natural 
barriers. 
The difficulty of making the distinction between recreational and medical cannabis 
has been increasing over the years, especially because research has been finding 
the major benefits of medical cannabis coming from the THC5 (the same 
psychedelic component in the plant used by recreational users to get the “high” 
sensation). “Can the same weed be legal and considered medical when prescribed 
by a doctor, and at the same time be illegal when someone buys it on the streets 
to have fun with friends?”. This and other non-coherent questions have been raised 
by a growing number of supporters and are the major reason why the majority of 
industry experts6 contacted believe the medical legalization will be followed by the 
liberalization of the consumption for adult use. 
However, in the long term, with the consolidation of the market, this distinction is 
expected to get clearer. While the industrial sector will be mostly represented by 
textiles, clothing, paper and cosmetics, the recreational segment is expected to be 
represented by dried flowers as well as several edible products. The medical 
segment is likely to share some similar products with the recreational, but with a 
stronger representation of cannabis-derived products such as oils, gels, or tablet 
pills. The recreational products are expected to have a higher composition of THC 
when compared with CBD7, while the medical products will have lower THC 
amounts. 
▪ CBD Vs THC 
Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the two main chemical 
components found in cannabis plants.  
THC is the psychoactive compound, that creates the “high” sensation. CBD has no 
psychoactive effects and is mostly used to relax the body. The two compounds 
interact with the endocannabinoid system, but they have very different effects. 
 
5 Tetrahydrocannabinol: a chemical component in the marijuana plant 
6 For this report several interviews were conducted, and experts in the industry were contacted e.g. responsible lawyer 
for the Portuguese branch of one of the largest multinationals, the owner of one of the shops were hemp is being sold, 
Aurora C-levels, several industry-related people (e.g. producers, supporters, researchers, among others) during the 
Cannadouro International Conferences that took place in Porto during November 2019 
7 Cannabidiol: a chemical component in a cannabis plant 
“THC is the psychoactive 
compound, that creates the 
“high” sensation. CBD has no 
psychoactive effects and is 
mostly used to relax the body” 
“Choice of locations is more 
dependent on strategic 
decisions such as proximity to 
the distribution network or 
legal barriers on importation, 
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Both can be used as recreational and medical8, but usually the recreational use 
tends to have higher percentages of THC (15%-20%).  
Depending on the seed, Sativa or Indica, the plant can have more CBD or more 
THC correspondently. Marijuana (Indica) has a higher concentration of THC while 
hemp (Sativa) has a higher concentration of CBD. Industrial Hemp has low 
amounts of THC (<0.3%) and CBD (<3%) and this is why it usually has distinct 
end-uses. Nevertheless, is not uncommon to hear about hemp-derived CBD 
products. 
Market Segmentation 
There are three main cannabis segments (Industrial, Recreational, and Medical), 
depending on the types of products and the level of CBD and THC.  
▪ Industrial Hemp Segment 
Especially big in the US, where it is common to hear about hemp paper or hemp 
clothes, the industrial cannabis sector has been using this derivation of the 
cannabis plant for more than 10.000 years.  
Due to its fast-growing characteristics9 and low production costs, the plant has 
been used to produce fibers that then are used to produce commercial products 
such as clothing, paper, textiles, biodegradable plastics, paint, insulation, biofuel, 
food, and animal feed. 
The industrial cannabis market (Figure 4) is expected to grow at a 14% rate until 
2025, to reach a $USD 15Bn market value. This growth is expected to be mostly 
driven by seed production, included in the composition of personal care products 
(e.g. cosmetics), food and beverages. 
Major players are mostly industrial companies that have been in the sector for a 
long time. Regarding geographical areas, Canada, China, France, USA, and 
Estonia (Figure 5), appear in the frontline with the largest hemp productions. 
Canada appears first, mostly due to the use of hemp-derived CBD to produce 
medical supplements10 such as oils and gels. However, hemp production to extract 
the fibers that are used for industrial purpuses (as paper, textiles, among others) 
 
8 The 10%-10% THC-CBD composition has been found to be the most effective for medical treatments. Source: German 
Institute for Medical Cannabis 
9 A hemp plant takes between two to four months until its fibers are ready for harvest 
10 Medical supplements are produced with hemp-derived CBD (due to the lower production costs), but are not 


















Figure 4: Industrial Hemp Global 
Market 2019-2025; Sources: Global 
Cannabis Report; New Frontier Data; 
Euromonitor 
 
Figure 5: Hemp production by country in 
2017; Sources: Global Cannabis Report; 
New Frontier Data; Euromonitor 
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is mostly located in China11, where cultivation is closer to the transformation sites, 
and final products are then exported all over the world. 
In terms of products, if the company positions itself only in the cultivation of hemp, 
then there are no relevant differences in the product in its raw form. However, if 
the company also does the transformation of the fibers, then it is important to have 
enough scale to compete for sales contracts with larger firms in the industries of 
textiles, paper, among others. For instance, firms like Aurora are not players in the 
industrial segment, and only some of them have small cultivations of hemp, or even 
excess stock of marijuana that then is sold for industrial purposes. 
▪ Recreational Segment 
Despite the evidence of cannabis use dating back to centuries ago, recreational 
use suffered a major backlash during the 20th century, being banned and 
considered as a hard drug all over the globe. Nevertheless, the 21st century new 
wave of liberal ideals aligned with recent findings of its health benefits have been 
bringing the topic back to international discussion and a recent wave of legalization 
of recreational use has been emerging. 
This recent wave of legalization has been associated with the increase of research 
in the field, that has been showing cannabis as a less harmful drug when compared 
with others such as alcohol or tobacco12. Besides that, all recent evidence is 
showing that the drug has also a low dependency rate (<10%), which comes 
against the common generalized idea of cannabis causing addictiveness and 
deaths. 
The Netherlands took the lead in regulating the legal use of cannabis for 
recreational purposes, using the well-known “coffee shops13”. However, the first 
country to officially legalize the production, trade, and use of cannabis for 
recreational use, was Uruguay in 2015 followed by Canada in 2018. The USA 
came next and several states have been legalizing the use of the plant (currently 
33 for medical uses and 11 for recreational purposes), and until 2025 it is expected 
to get closer to the 30-state threshold14 where it automatically needs to be 
discussed at a federal level. Spain recently introduced a similar approach as the 
Netherlands and appears as the first in line for full legalization which is expected 
 
11 Similar to other industrial sectors, China offers cheaper and qualified labor force, larger production facilities, and a 
robust legal framework for production 
12 Source: Batista Leite, Ricardo. Ploeg, Lisa. “The Road towards the Responsible and Safe Legalization of Cannabis 
Use in Portugal”, February 2018, Ata Médica Portuguesa 
13 Closed spaces where trade and consumption are allowed 
14 In the US after 30 states pass a similar law, it goes directly for approval at a federal level 
“Research in the field, that has 
been showing cannabis as a 
less harmful drug when 
compared with others such as 
alcohol or tobacco” 
“While in the medical sector 
the regulatory restrictions 
create strict barriers to enter 
the market, the recreational 
segment is expected to be 
more fragmented, similar to 
what happens with craft beer 
in the beverages sector” 
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to happen until 2022. Nevertheless, Spain is not alone, and until 202515 other 
countries such as Portugal, South Africa, Italy, Switzerland, Mexico, Columbia, are 
also expected to legalize the recreational use, to fight the already existent parallel 
economy, and create a strict regulatory framework over the product, closer to what 
can be found in alcohol or coffee markets. 
Larger cannabis companies (e.g. Canopy Growth, Chronos, Aphria, Tylray, 
Aurora, among others), which started their activity with the production for the 
medical sector, have been taking advantage of the wave of legalizations to adjust 
their focus, especially considering the size of the recreational segment (Figure 6). 
Nevertheless, while in the medical sector the regulatory restrictions create strict 
barriers to enter the market, the recreational segment is expected to be more 
fragmented, similar to what happens with craft beer in the beverages sector. 
 
Figure 6: Cannabis Recreational Global Market; Sources:Aphria Annual Report; Prohibition 
Partners; Global Cannabis Report; New Frontier Data; Euromonitor; UN ODC 
Despite being in parallel economy, it is a market already mature in the majority of 
countries that are about to legalize, where there is relatively easy access to “weed”, 
with consistent supply and high acceptance rates by the population16, and where 
the average consumer is no longer associated with delinquency17. 
For these reasons, as shown in Figure 6, the recreational market is not expected 
to expand immensely in terms of size. The trend will be mostly a shift from the 
illegal trade (>90% of the total recreational market in 2015) into a regulated 
market by 2025 (when the illegal market is expected to represent <40% of the 
total recreational market).  
 
15 The vision is shared by largest political lobby groups, doctors, and lawyers of those countries, and is in line with the 
evolution of the regulatory frameworks verified over the last quarters 
16 In 2018, 61% of Americans thought “weed” should be legalized for adult-use; Source: Pew Research Center 
17 In the US the average consumer in the recreational segment is thirty-seven years old and married with children; 
Source: Euromonitor 
“Despite being in parallel 
economy, it is a market 
already mature in the majority 
of countries that are about to 
legalize, where there is a 
relatively easy access to 
“weed”, with consistent 
supply and high acceptance 
rates by the population” 
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In terms of production, most companies opt to have different production sites, both 
for cost reduction and to be closer to the distribution networks. This is possible 
because cannabis in its dried form can travel across countries without losing its 
characteristics, and therefore companies like Aurora have several production 
facilities in countries with similar weather conditions (particularly in the tropics and 
equatorial regions such as Columbia, Portugal, Morocco, Mexico, among others) 
as well as lower labor and real estate costs. Also, due to strict legislation, some 
countries18 require that production cannot be imported, and if firms want to sell in 
those countries, they need to have physical facilities there.  
In terms of products, raw weed and prerolls are expected to continue to be the 
major way of consumption (>50%), while a rise of vape instruments is expected 
since the reduced amount of inhaled smoke has been perceived as less harmful 
for the body. Also, the practicality of not needing to carry all the material to roll a 
joint19 is an important factor that contributes to the acceptance of this all-in-one 
solution. 
Other products that are expected to have an impact in the industry, and also in the 
recreational segment, are the products responsible for the so-called “Cannabis 
2.0”, referring to the new wave of cannabis-derivative products, made out of 
cannabis extracts, such as cookies, beverages, tea, among others. Due to the lack 
of legislation, these products have been produced using hemp20 but the shift into 
higher THC-level products is expected to happen as soon as the legislation moves 
forward. 
The products across different companies do not vary immensely, and although 
some companies focus on specific products (e.g. only producing gels or oils), in 
the recreational segment the type of product21 weights more in the purchase 
decision of a consumer rather than the brand. And that is one of the major reasons 
for the importance of the distribution channels, and a good distribution network as 
well as strong relationships with the authorities in each country.  
This happens because in terms of distribution channels each country still has a 
unique legislation regarding the topic as well as different distribution models. For 
example, while in Canada people are allowed to buy online from companies’ 
websites, in Uruguay they need to be registered in an official list of consumers and 
 
18 This is more common in the medical sector where countries like Italy do not allow imports from outside, but similar 
restrictions are expected to be seen in the recreational sector and companies will need to face those barriers 
19 Materials might include papers, filters, tobacco, weed, grinder, amongst others 
20 E.g. Cannabis Store Amsterdam has over 170 stores in Southern Europe and is using hemp to produce several products 
(e.g. edibles, raw weed, drinks, chocolates, among others) 
21 The consumer cares about the type of strain or quality they are buying more than the brand that was responsible for the 
production, creating space for smaller businesses to focus on niche products 
“Rise of vape instruments is 
expected since the reduced 
amount of inhaled smoke has 
been perceived as less 
harmful for the body” 
“In Europe (and similar to 
what is happening in the US), 
the models under discussion 
would be similar to the alcohol 
market in the Nordics, where 
there are specific stores with 
the license to sell alcohol and 
supermarkets are only 
allowed to have beverages 
until a certain alcoholic level 
(or even alcohol-free).” 
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the product can only be found in pharmacies or other specific stores ruled by the 
government. In Europe (and similar to what is happening in the US), the models 
under discussion are similar to the alcohol market in the Nordics, where there are 
specific stores with the license to sell alcohol and supermarkets are only allowed 
to have beverages until a certain alcoholic level (or even alcohol-free). 
▪ Medical Segment 
Despite stories dated from 3000BC mentioning that the cannabis plant was used 
in Chinese treatments, it was not before this last decade that the industry really 
experienced an explosive growth. Cannabis used for medical purposes has been 
receiving a good acceptance (especially in America and Europe) in recent years, 
due to positive feedback and the effectiveness of treatments using cannabis22. 
Both CBD and THC can have good medical benefits, although THC has been 
associated with the highest results. Nevertheless, CBD does not cause the 
psychedelic effect and commonly cancels out the effects of THC, and therefore is 
usually also part of the product. 
The medical cannabis market is expected to be given more attention in the next 
years due to the increase in its use in treatments. Started in Canada, and followed 
by the United States, the trend is shifting to Europe where countries such as 
Germany, Spain, Portugal, Switzerland, among others, have been implementing 
cannabis-drug solutions23 into their range of options for treatments of Sclerosis, 
Parkinson, Diabetes, among others. 
 
Figure 7: Medical Global Market; Sources: Aphria Annual Report; Prohibition Partners; Global 
Cannabis Report; New Frontier Data; Euromonitor; UN ODC 
As shown in Figure 7 the global market is expected to present an annual growth of 
around 17% over the next years to reach a $USD 40Bn valuation by 2025. USA 
($USD 10Bn), Canada ($USD 5Bn), Germany ($5bn), and smaller markets such 
 
22 Source: German Institute for Medical Cannabis 
23 Several drugs have been approved by national health agencies and are already part of the spectrum of options for the 
doctors to prescribe 
“Both CBD and THC can have 
good medical benefits. THC 
has been associated with the 
highest benefits. However, 
CBD does not cause the 
psychedelic effect and usual 
cancels out the effects of 
THC” 
“Pure medical cannabis 
companies (i.e. Pharma) are 
still on the rise, but GW 
Pharmaceuticals (market cap 
$USD 40Bn) is leading the race 
and has developed several 
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as Spain, Netherlands, Italy, South Africa, Israel, Switzerland, Mexico ( with around 
$1bn market potential), are expected to be the countries leading the growth.  
In terms of players (Figure 8), the most-known companies in the sector include 
Canopy Growth (market cap $USD 7Bn), Aphria (market cap $USD 5.5Bn), Aurora 
(market cap $USD 3.7Bn), Curaleaf (market cap $USD 2.7Bn), Chronos (market 
cap $USD 2.5Bn) and Tylray (market cap $USD 2Bn). Although these companies 
classify themselves as medical, they are mostly responsible for the cultivation of 
the plant itself. Therefore, their products are usually either the dried flower itself or 
lower technology-intensive products such as oils, gels or drops. Pure medical 
cannabis companies (i.e. Pharma) are still on the rise, but GW Pharmaceuticals 
(market cap $USD 40Bn) is leading the race and has developed several products 
for multiple Sclerosis disease24. 
Nevertheless, medical cannabis has been the solution found to start the talks for 
the legalization of sales of weed in its dried flower state (that will be used to smoke). 
This happens because if someone smokes cannabis to feel better both 
psychologically (happier, relieved) and physically (to help them to relax after a 
workday), then cannabis will start to compete directly with pain killers or anti-
depressives even before being used for more degenerative diseases such as 
Parkinson or Multiple Sclerosis.  
In terms of competition, it can vary considerably among the different industry 
segments. Industrial cannabis represents a “heavy” industry25 and therefore, has 
generated economies of scale in mass production, allowing for some concentration 
in suppliers26. The recreational segment seems to be a more competitive market 
served by several players, some of them regional27. Finally, medical cannabis is 
no more than a pharmaceutical sector, involving high costs in R&D, and requiring 
major working capital investments in inventory, regulations, expansion, among 
others. Therefore, the production is capital-intensive, requiring relevant capex 
investments28. Due to these high barriers to entry (and exit), it seems that this last 
segment is the natural oligopoly that after some years of intense M&A activity and 
integrations, will end up with few big players that will compete against each other 
to guarantee the highest market share. 
 
24 E.g. Sativex (with both THC and CBD) was already approved and can be found in several European pharmacies 
25 The industry requires intense Capex with production and transformation machines creating high barriers to entry and 
creating economies of scale with an increase in production. 
26 There is a strong concentration in production companies, mostly with origins from China or Canada  
27 Once adult-use is legalized, part of the recreational segment is expected to be targeted by smaller players with specific 
or tailored products (similar to what was verified with craft beer in the beverages segment). 
28 Investments required are analyzed in more detail over the next sections of the report 
“Medical cannabis is no more 
than a pharmaceutical sector, 
involving high costs in R&D, 
and requiring major working 
capital investments in 
inventory, regulations, 
expansion, among others” 
Figure 8: Cannabis Players by Market 
Cap November 2019; Source: Bloomberg 
“Brand image assumes more 
relevance than in other 
segments since doctors need 
to trust the companies in order 
to prescribe the drugs. Some 
of the transformed products 
are protected by patents and 
that is the reason why R&D is 
important in this segment” 
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In terms of products, for companies like Aurora, oil and gel are the ones growing 
the most, especially because older people feel more comfortable to take it. The 
ingestion can be done with drops or by putting it into a vaping instrument. Also, 
some common tablets have been emerging and are already present in some 
European pharmacies.  
With medical cannabis, there is some differentiation in products across different 
companies, especially because the majority of products suffered transformations 
(e.g. pills, sprays, gels, oils) and are not just cannabis in its dried form. Also, the 
brand image assumes more relevance than in other segments since doctors need 
to trust the companies in order to prescribe the drugs. Some of the transformed 
products are protected by patents and that is the reason why R&D is important29 
in this segment. Nevertheless, lower added-value products such as gels or even 
cannabis in its dried form have been given medical properties in several countries 
(such as Germany or Portugal), allowing companies like Aurora to be present in 
the market without major investments in R&D. 
Like recreational cannabis, plantations and production facilities have been moved 
to countries such as Columbia, Mexico, Portugal, among others, due to its cheap 
labor force and good weather conditions, making them ideal places30 for the 
cannabis development.  
Due to the tendency for market concentration in terms of suppliers, it is expected 
for major firms to have large production facilities in the mentioned countries, as 
well as having comprehensive distribution networks that take the product to the 
consumer. Nevertheless, medical cannabis has strict regulations and audits during 
the production process, and the distribution model will depend severely on the 
legislation within the country, representing a major issue these companies will 
need to overcome31. While in Canada, Aurora is allowed to have an online 
distribution service to customers that are enrolled in a subscription list (after an 
appointment with a doctor), European countries are expected to follow the Uruguay 
example, where the drugs will be mostly distributed in pharmacies.  
 
29 GW Pharmaceuticals have been the pioneer in clinical trials with several transformed medical drugs, while companies 
like Aurora have mostly focused on lower value added products like gels or cannabis in its dried form that are expected 
to be given similar medical properties, allowing for the company to compete in the segment with a lower R&D expense. 
Source: German Institute for Medical Cannabis 
30 The cost per gram of dry flower of around USD 2$ in Canada can be decreased to close to USD $0.50 in Columbia; 
Source: Financial Times 
31 For example, Aurora was one of the three companies which were allowed the supply of cannabis in Germany without 
the need for production facilities in the country, which represents a major entry barrier for other companies and will 
allow Aurora to leverage this in the European market 
“Cost per gram of dry flower of 
around USD 2$ in Canada, can 
be decreased to close to USD 
$0.50 in Columbia” 
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Figure 10: Shareholder Structure; Source: Bloomberg 
Company overview 
Company description 
Aurora Cannabis Inc. is a leading integrated cannabis company headquartered in 
Edmonton, Canada, engaged in the production, distribution, and sale of cannabis 
products. Currently, Aurora operates in three different segments: Medical 
Cannabis, Recreational Cannabis and Industrial Cannabis.   
  
Figure 9: Aurora Geographical Presence; Source: Aurora Annual Report 
Additionally, Aurora operates in 25 countries (Figure 9), and has undertaken 17 
strategic acquisitions and partnerships across the value chain since 2016.  








Until 2017, the shareholder structure was mainly composed of individuals and the 
founders (Steve Dobler and Terry Booth), who were among the largest 
shareholders. Nonetheless, since 2017 as the firm expanded and the industry 
sparked the interest of many investors, institutional investors started to invest in 
the company. Nowadays, more than 50% of the company is held by institutional 
advisors, such as Vanguard, BlackRock, ETF Managers groups, among others.  
“Nowadays, more than 50% of 
the company is held by 
institutional advisors, such as 
Vanguard, BlackRock, ETF 
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In what regards the individual ownership, the president of Aurora, Steve Dobler, is 
the current largest individual shareholder of the firm, followed by the CEO, Terry 
Booth, detaining around 2% and 1% respectively32.  
Nonetheless, given cannabis is not legal at a federal level in the US, Aurora is still 
only listed over the counter (OTC) and not in the exchange33. Likewise, a downside 
of being listed in OTC is that large Investors who would want to invest in the 
company, are not allowed to due to portfolio policy restrictions34. The same 
happens in Europe as it is not legalized in most countries, which also limits the 
access to European investors.  
History and past acquisitions 
Although the company’s first license to sell medical cannabis was only given in 
2014, the firm was established in 2006, and since then, Aurora has been building 
and operating numerous facilities not only in Canada but also in Europe35.  
Aurora undertook multiple acquisitions for the past years, and today, the firm’s 
portfolio includes names such as CanniMed and MedReleaf, two large cannabis 
producers.  







Figure 11: Company Acquisitions and Stock price performance ($CAD); Source: Aurora annual report 
For instance, back in 2016, the CanvasRx acquisition gave access to one of the 
largest databases on cannabis strains and physicians, creating synergies in 
reaching out to the medical community. In 2017, among the numerous acquisitions 
 
32 Source: Bloomberg 
33 OTC is a decentralized market whereby security is traded via a broker-dealer-network. Centralized exchange is an 
organized and regulated market where securities are traded through a centralized source facilitating a safer and easier 
transaction. 
34 Illiquidity could be a restriction. For instance, if a shareholder decides to sell a large share of his capital, there might 
not be the number of buyers willing to buy it and likewise the bid-ask spread can be too large.  
35 Company holds 15 production facilities- 4 in Europe, 10 in Canada and 1 in Uruguay; Source: Aurora annual report  
“Given cannabis is not legal at 
a federal level in the US, 
Aurora is still only listed over 
the counter (OTC) and not in 
the exchange. Likewise, a 
downside of being listed in 
OTC is that large Investors 
who would want to invest in 
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was Pedanios Pharmaceuticals, Germany’s largest distributor of cannabis to 
pharmacies, which represented a key step to enter the medical cannabis in the 
European market. More recently, the company acquired Whistler, a Canadian 
cannabis iconic brand known for providing premium quality cannabis. Nonetheless, 
by looking at the figure above, those are considered relatively small acquisitions 
as the capital raised for most deals represents around 1% of Aurora market cap 
and did not have a large impact on the firm share price.  
On the other hand, on 24th January 2018, Aurora acquired CanniMed for $CAD 
1.2Bn. Although their reputation and capabilities were significantly strong in the 
medical market and could further leverage the growth and penetration of one of 
the main segments of the international cannabis market, the market reacted 
negatively, dropping two consecutive days by a total of around 15% based on the 
previous day closing price of CanniMed36.  
On 14th May 2018, MedReleaf’s acquisition was marked as the largest cannabis 
takeover in the industry after Aurora acquired its rival producer for $USD 2.6Bn. 
The firm paid $CAD 29.4 per MedReleaf common share, corresponding to a 
premium of 20% which the market might have interpreted as an expensive deal 
since the Aurora stock dropped the next three days by a total of 14%37. In terms of 
synergies however, the company was able to produce on a larger scale in Canada, 
and to be present in other provinces, securing a leading position as a top-tier 
licensed producer in cannabis.  
In fact, when looking at the chart performance of the firm, the premium over these 
mergers would not fully explain the drop in price. Likewise, the issuance and selling 
of shares to finance these acquisitions is another relevant factor that affected the 
stock price because older shareholders reacted negatively to the dilution caused 
by new issuances.  
When looking at competitors’ M&A activity, similar patterns can be observed. Most 
of the large deals were financed through equity and companies look to merge both 
at a vertical and horizontal level. For example, Canopy Growth emphasized its 
focus on driving product innovation by increasing research and better margin 
products having likewise acquired companies such as BioSteel Sports Nutrition 
and Beckley Canopy Therapeutics38. Curaleaf is focused on the US market and 
acquired companies such as Grassroot and Cura Partners, both vertically 
integrated companies and state-regulated cannabis businesses. 
 
36 Source: PR Newswire “Aurora Completes CanniMed Acquisition”, May 2018, reported by Aurora 
37 Source: PR Newswire “Aurora Cannabis to Acquire MedReleaf”, May 2019, reported by Aurora 
38 Source: Canopy Management Discussion and earnings report 2019 
“Aurora acquired CanniMed 
for $CAD 1.2Bn (…), the 
market reacted negatively, 
dropping two consecutive 
days by a total of around 15% 
based on the previous day 
closing price” 
“On 14th May 2018, 
MedReleaf’s acquisition was 
marked as the largest 













As mentioned before, the firm operates in three distinct segments: Medical, 
Consumer and Industrial Cannabis. Majority of sales still come from Canadian 
market (over 90%), while the remaining are mostly driven by European market, the 
one expected to represent the major driver Aurora´s growth in the next years, 
The firm currently has three main different product lines: dried cannabis, cannabis 
extracts and others (e.g. vapers). Dried cannabis is the most recognized form of 
the substance for all cannabis consumers. Cannabis extracts is a more recent line 
of business, which includes oils, gels, and other cannabis-derived products. 
Finally, “others” represent vapers and other products related to the consumption 
of the substance. Likewise, they can all be used for both medical and recreational 








Before the legalization in Canada, Aurora ‘s main source of revenue was solely the 
medical business39. Only in October 2018, the Federal Cannabis Act40 was settled, 
formalizing the legalization of cannabis in the North American country. 
Subsequently, the recreational cannabis revenues boosted across the industry and 
in 2019, the segment represented around 43% of Aurora’s total revenues.  
While industrial segment is not the company focus, on the other hand, the medical 
business, which represents nearly half of the total revenues, is expected to 
increase over the next years (in particular in the European market).  
For example, In Europe, the company currently sells in Germany, Malta, Poland41 
and, more recently, in Italy. In September 2019, the company signed a contract 
 
39 Until 2017, the firm only sold dried cannabis. By 2017, the company started selling dried cannabis to the EU and 
cannabis extracts in Canada within the medical sector 
40 Health Canada is the organization responsible for overseeing national health and regulates the cannabis sector. 
41 Through its subsidiary Aurora Deutschland GmbH, it ships products to pain treatment centers and hospitals. 
“Cannabis extracts is a more 
recent line of business, which 
includes oils, gels and other 
cannabis-derived products” 
Figure 13: Aurora revenue breakdown; Source: Aurora annual report 
Figure 12: Industry revenue company 
breakdown ($CAD); Sources: Company 
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deal whereby Aurora will be one of the main suppliers of the Italian government 
regarding medical supply for the next two years42.  
Nonetheless, Aurora’s competitors are also investing in the European market. For 
instance, Canopy Growth is currently producing cannabis for medical and cosmetic 
purposes in Czech Republic and has established itself in Denmark which might be 
one of the largest production sites in Europe43. Moreover, Canopy reported early 
this year that they formed a partnership with a Spanish morphine producer called 
Alcaliber which signals the interest of the Canadian company to tackle the 
European market. Additionally, Tilray holds more than 20 hectares of indoor and 
outdoor cultivation in Portugal as well as facilities for manufacturing, processing, 
and research. Finally, Aphria continues to expand its footprint in Europe through 
strategic partnerships such as ASG44.  
▪ Cost structure 
The company strategy of incurring heavy M&A activities has been successful in 
helping to decrease the cost per gram of dried cannabis sold given they have been 
realizing more economies of scale45 by producing larger volumes through their 
facilities such as Aurora Sky, River and Ridge. In addition, the lower conversion 
cost46 due to the technology development has also proven to be key in lowering 
the production cost per gram. Although decreasing for the past quarters, the costs 
per gram are expected to stabilize once M&A and respective synergies are fully 
established and production facilities reach their maximum production capacity and 






42 According to the annual report, Aurora is expected to supply a minimum of 400kg of medical cannabis over a two-
year contract. The fact that its German subsidiary Pedanois has a GMP certification was critical to win the tender offer  
43 European Cannabis Report by Prohibition Partners 
44 High capacity EU-GMP certified lab in Malta 
45 Source: Aurora annual report 
46 Cost of converting the dried cannabis into an oil form. 
“Company signed a contract 
deal whereby Aurora will be 
one of the main suppliers of 
the Italian government 
regarding medical supply for 
the next two years” 
 
 










Moreover, other yet important expenses of the cost structure such as packaging 
saw an increase in the last year (Figure 15). Most of this cost increase was due to 
the regulatory purpose mandated under the Cannabis Act47 which obliges 
cannabis companies adopting new packaging, excise tax stamping among other 
requirements and likewise, is not expected to graduate increase the packaging per 
gram sold48. 
When compared to the most of his competitors, Aurora presents one of the lowest 
costs per gram among its largest competitors such as Canopy and Tilray49. The 
rest of the competitors presents a lower cost however they sell nearly half 









47 Law which legalized the recreational cannabis in Canada 
48 According to Aurora annual report, sale cost per gram sold = cost per gram to produce + packaging cost per gram 
49 Cost per gram sold was calculated by dividing Total Sales by Kilograms sold in order to compare with peers since not 









Packaging per gram sold
+19%
(%)
Figure 15: Packaging Cost per gram; 
Source: Aurora annual report; Note: 
Packaging per gram sold consists of 
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Cost per gram produced vs Kilograms produced
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(Kg) ($CAD)
Figure 14: Cost to produce and quantity produced ; Source: Aurora annual report; Note: 
Cash cost to produce per gram sold  consist of Total Cost of  Sales adjusted for depreciation, 
cost of accessories, packaging costs and other costs divided by Kilograms sold  
 
 





  PAGE 19/32 
 
 







Figure 17: Aurora vs cannabis market; Note: Cannabis market was computed by averaging the daily 
returns of Aurora and Competitors; the graph represents the total return since 19/07/2018 
Until the last quarter of 2019, Aurora was overall outperforming the cannabis 
sector. However, for the last 5 months, the stock has been underperforming the 
industry by a significant percentage (Figure 16) and there are three reasons 
suspected of having caused such selling: 
1. Continue stake dilution through heavy equity financing to fund M&A 
activity: although not having a direct impact in stock price, it has a bad 
signaling effect for investor, because it exposes the lack of access to debt 
capital markets that affects the industry. 
2. Continue negative EBITDA reported despite increase in revenues: 
although normal in an early stage company, it still means that the company 
is not being efficient at an operational level, pushing investors away. 
3. Legalizations happened as expected, but bureaucracies associated were 
not agile enough: this created several problems in the free trade of the 
product and sometimes leaving space for the black market (e.g. in 
Canada, the lengthy process to get a selling license, delayed several store 
openings that were expected, contributing for inventory accumulation) 
Moreover, in November 2019, Aurora announced that 94% of the holders of 
unsecured convertible debt worth $CAD 230M50 converted their debt into stock at 
a 6% discount51. The stock dropped a total of nearly 30% the following 3 days as 
the transaction implied an issuance of more 69.1M shares, a move implied 
wariness for equity investors.  
 
50 Represented a total of the 54% of Total debt (the rest is mainly Accounts payable and accrued liabilities -  
51 Sources: Newswire - “Aurora Cannabis Announces Pricing of Early Amended Conversion Privilege for Convertible 









Figure 18: “Return on Invested Capital”, 
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In line with the industry, Aurora Cannabis’s stock price has been dropping 
throughout the year, mostly due to the mismatch between the expectations that 
were created for the legalizations, which ended up taking longer than expected. 
Also, the slow regulatory framework made licenses for distribution selling points to 
take longer than expected, contributing to inventory accumulation and a slower 
increase in sales than was expected. 
Although this had a negative impact on the overall industry, the forecasts for the 
next five years show an optimistic view of the sector. The recreational legalization 
at a federal level is being discussed in the US, the surge of the European market, 
and the changing in opinions on cannabis by governments around the world, all 
contribute to the optimistic view on the sector. 
Companies like Aurora will benefit a lot from this, especially because a strict 
regulatory framework is expected, where products will be subject to constant tests 
and quality proofs. Due to high barriers to enter such as intensive capital 
expenditures to face this regulation, the market will probably tend to consolidate 
into the already-established firms, which have the strongest distribution networks 
and the largest production facilities. 
Therefore, Aurora is expected to start having positive EBITDA within the next four 
years and to be cash flow positive until 2026 when the markets start to consolidate, 
and no major Capex investments will be required. 
Main Forecasts Reasoning 
▪ Sales and Margins Margin 
Key Financials (000´s $CAD) 2017 2018 2019 2020E 2021E 2022E 2023E 2024E 2025E 
Revenues 18.067 55.196 281.097 626.929 1.066.058 1.671.970 2.140.978 2.740.795 3.323.011 
% Δ YoY n/a 206% 409% 123% 70% 57% 28% 28% 21% 
Gross profit 10.120 37.907 161.354 419.571 696.524 1.067.630 1.383.884 1.768.464 2.154.082 
Gross Margin 56% 69% 57% 67% 65% 64% 65% 65% 65% 
EBITDA (16.626) (90.333) (253.147) (274.009) (182.977) (71.956) 227.300 474.418 893.172 
EBITDA Margin -92% -164% -90% -44% -17% -4% 11% 17% 27% 
Figure 19: Sales, Margins & EBITDA evolution; Data provided in the report is in current prices, already considering inflation 
Overall, the sales of Aurora Cannabis are expected to continue with a strong 
increase in the next years, in particular the next three years, which will be important 
Aurora is expected to start 
having positive EBITDA within 
the next 4 years and to be cash 
flow positive until 2026 
The recreational legalization at 
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for the future of the industry52. The gross margin is expected to be higher than in 
201953, once operations get stable. 
In terms of distribution by segment (figure 20), the surge of the recreational 
segment in 2019 is expected to continue over the next years and solidify with the 
expected emergence of the European market, in particular after 2023, for the legal 
reasons mentioned above and further explored in a deeper analysis later on. 
 
Figure 20: Sales Distribution by Segment 
Regarding sales distribution by region (figure 21) the concentration in North 
America is expected to decrease over the years, due to the rise of the legalization 
in the European market (and where Aurora is focusing its investment), as well as 







Figure 21: Sales Distribution by Geography 
 
52 The next three years are expected to see the consolidation of the industry in the US with the discussion at federal level 
to take place, and the beginning of the recreational liberalization in Europe 
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▪ Net Working Capital 
Although the company still has a typical early-stage structure54 of cash conversion 
cycles, it is expected to mature in line with the industry55 within the following years.  
For example, the average metric of days payable is currently close to two years, 
which can be seen as unrealistic in the future, and therefore were projected to 
decrease in line with the industry.  
Key Financials 2017 2018 2019 2020 2021 2022 2023 2024 2025 
Days Receiva. 46 97 131 131 120 120 120 100 100 
Days Inventory 354 625 472 400 350 350 300 300 300 
Days Payable 392 642 620 500 400 350 300 250 200 
Figure 22: Average Days of Net Working Capital  
Regarding the average days receivable, they are not expected to suffer major 
changes, and were forecasted to be in line with research data, in between three to 
four months until the collection of payments. 
Lastly, the accumulation of stock over the last year is expected to be fully solved 
by next year, and inventory is not expected to have a rotation over one year when 
operations are mature. 
▪ Capex 
 
Figure 23: Capex forecast 
 
54 Start-ups usually have a shortage of cash flow and tend to extend payment days and force to decrease the days 
receivable. 
55 An analysis of the tobacco industry was performed and, in addition to a comparison with the main competitors, used as 
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Capex  by Type ($CAD)
Expansion Capex Maintenance Capex
($CAD)
“Aurora is expected to 
continue financing its future 
acquisitions and operations 
next year mainly through 
equity issuances”  
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following years”  
 
 





  PAGE 23/32 
 
 
The Capex is expected to be one of the largest costs of the company due to the 
strategy of expanding and penetrating new markets. The firm has yet to find a 
strategy to enter the US market and that could potentially be in the form of an 
acquisition. Moreover, the company will most probably continue with the 
investments in Europe since only two of its facilities are already operating under 
the EU-GMP56 practices. 
Therefore, the expansion capex was forecasted to continue strong over the next 
three years, and then decrease in the following years, where a maintenance capex 
will be necessary to maintain the assets. 
▪ Debt and Equity 
 
Figure 24: Aurora Financing Resources 
The difficult access to debt markets makes it expectable for Aurora to continue 
financing its future acquisitions and growth through equity issuances in the medium 
term.  
Later, as the firm turns operating cash flow positive, it is expected to restructure its 
capital structure and leverage itself in a sustainable way57. 
Valuation Methods 
Different valuation methods58 were performed in order to eliminate inconsistencies 
and have a robust valuation. Methods that will be given more relevance are the 
valuation by multiples and the valuation by discounted cash flows. Nevertheless, 
for high-growth companies with negative cash flows such as this one it is not 
 
56 Good Manufacturing Practice: European Union production standards requirements. 
57 The Forecast was performed with a long-term Net Debt/EBITDA target slightly above 2x, in line with similar 
industries. 
58 For FTE, APV and WACC to be exactly the same, the capital structure used for the calculations should be adjusted 
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uncommon to apply types of valuations usually seen in venture capital fields (e.g. 
3-stage model59), but it was decided to not consider these valuations due to the 
lack of detail they present. 
 
Figure 25: Share prices by valuation method 
It is possible to verify a gap between the average valuation derived from intrinsic 
valuation methods and the valuation derived from multiples, leaving a range 
between $CAD 6 – 9 for the share price projection for March 2021, higher than the 
current stock price (around $CAD 3). 
▪ Valuation by multiples 
Although it is more common to use multiples such as EV/EBITDA, the fact that 
Aurora is a high-growth company with negative results leads to the choice of other 
kinds of multiples when performing the valuations.  
Multiples60 EV/Sales P/Sales 
Aurora 8.51x 7.37x 
Tilray 14.30x 12.10x 
Canopy 19.40x 20.20x 
Aphria 5.10x 10.60x 
Hexo 7.01x 4.24x 
Cronos 11.83x 22.19x 
Curaleaf 14.80x 15.40x 
Industry Average 11.56x 13.16x 
Figure 26: Multiples by Company; Source Company´s Financial Statements 
Industry averages were computed for both multiples of comparable firms and 
multiples of past transactions and used for valuation. 
EV/Sales of 11.56x and Price/Sales of 13.16x were used to forecast the share 
price for FY2020 ($CAD 7.7 and $CAD 9.9, respectively). 
 
59 A derivation of the Gordon Growth Model allows for different growth rates throughout the years (i.e. the stages), 
which fits an early-stage company of this kind.  
60 Firms chosen where the most comparable with Aurora in terms of company organization, product lines and 
geographies covered 
0 2 4 6 8 10 12
1. DCF - WACC
2.1. Multiples Comparables EV/ Sales
2.2.. Multiples Comparables P/ Sales
3. Multiples Past Transactions TV/Sales
4. APV
5. FTE
Share Price $CAD by Valuation Method
9.25.7
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In what relates to past transactions, the transactions which occurred within the 
industry were analyzed to understand the most representative ones61. A multiple 
EV/Sales of the acquired company of 13.3x was computed and used for valuation 
purposes (share price of $CAD 10). Nevertheless, the use of the multiple for 
valuation purposes should be cautious because usually it might be inflated due to 
common premiums paid on transactions (e.g. control, majority, among others). 
▪ Valuation by discounted cash flows 
The levered betas of all companies within the sector (mentioned above) were 
calculated by plotting the regressions of their weekly returns against those of the 
S&P500. 
 An industry median was considered and after adjustments for capital structure, a 
beta of 1.12 was computed for Aurora.  
The market risk premium of 5.5% was considered62 to get into a cost of equity of 
7.43%. The cost of debt was computed by calculating the company interest 
coverage ratio and subsequently attributing a synthetic rating accordingly which 
would then correspond to a default spread63. Lastly, the Rd was computed by 
summing the risk free, which used the Canada 10-year rate, and the default 
spread. A target Debt to Equity ratio was based on the median of the tobacco 
industry, considered a solid example of what the cannabis industry will turn into (in 
terms of distribution channels, players, or even strategies).  
Cash flows were forecasted until 2035 and a growth rate of 3.5%64 was used to 
calculate the terminal value. Finally, a WACC of 6.76% was computed and used 
for valuation purposes (for a share price of $CAD 5.7). 
Main Risks & Scenario Analysis 
Finally, a scenario analysis was performed on what are considered to be the major 
risks for the company over the next years. The growth rate of the legalizations 
around the world, the entrance into the US market, the M&A strategy, among 
 
61 Most relevant transactions within the sector were filtered, and only largest deals related with main companies were 
considered for the multiple calculation, and then outliers were excluded in order to give a more robust number. The full 
list can be seen in the attached excel file 
62 “Forecasting Stock Market Returns”, 2010, Miguel Ferreira and Pedro Santa Clara 
63 Given Aurora interest coverage ratio around 4.3x, synthetic rating attributed was A- and the corresponding default 
spread is 3% (“Ratings, Interest Coverage Ratios and Default Spread”, New York University, 2019)  
64 Average of RR*RONIC (T. Koller, M. Goedhart, and D. Wessels, Valuation: Measuring and Managing the Value of 
Companies, McKinsey & Company, John Wiley & Sons, 5th ed.) for the last two years was equal to 4.1%, and then an 
average was made between that number and the nominal growth considered based on historical data (Canada 1958-2019 
Nominal Growth of 3.1% and inflation of 1.7%) and economic official growth forecasts by Canada Government Official 
Website 
Rf 1.51% 
Market risk Premium 5.50% 
Be (Beta Re-levered) 1.08 
Re (Lev. Cost of equ.)  7.43% 
  
Interest Cov. Ratio 4.32x 
Synthethic Rating  A- 
Typical Default  3.00% 
Risk Free 1.51% 
RD (Cost of debt) 4.51% 
  
Re (Lev. Cost of eq.)  7.43% 
Target D/E 20.00% 
Rd (Cost of debt) 4.51% 
Tax Rate 27.00% 
WACC 6.74% 
Figure 27: Inputs for Valuation 
“The growth rate of the 
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others, are all important factors associated with risks for the company, if they do 
not materialize as planned. 
The first analysis was performed on the strategy to enter the US market. Aurora is 
still not selling in the US, which is a competitive market with several small American 
players. However, with the consolidation of the market, it is expected that major 
firms will manage to capture some market share.  
A base scenario where Aurora captures around 2%65 of the market was the one 
used for main valuations. Then, a scenario where Aurora keeps outside the US 
market and a scenario where Aurora will gain a stronger share of the market were 
calculated. 
Valuation Method Keep Outside US Market Base Scenario Gain Stronger Position In US 
1. DCF - WACC 4.2 6.5 9.9 
2.1. Multiples EV/ Sales 6.7 7.8 8.9 
2.2. Multiples P/ Sales 8.7 9.9 11.2 
3. Multip. Transact. TV/Sales 8.8 10.1 11.3 
4. APV 4.7 6.8 10.0 
5. FTE 5.3 7.1 9.8 
Figure 28: Scenario Analysis on the Entrance in US Market and its impact on Stock price ($CAD) 
Based on what was described throughout the report, the base scenario seems to 
be the most reasonable and was attributed a 75% probability for valuation 
purposes. The US is a market in consolidation, which is starting to open to large 
international companies, and Aurora needs to be taken into consideration. 
Nevertheless, this is a competitive market and therefore a lower share (when 
compared to its share in Canada) was used. 
The other two scenarios were not considered to have a high probability (10% for 
keeping outside the US, and 15% for gaining a stronger position), but it is relevant 
to analyze the impact that they would have on the share price (e.g. DCF valuation 
for the scenario outside the US gives a $CAD 4.2 share price which is close to 
what current markets are pricing) in order to understand which implications they 
might have in Aurora’s valuation. 
Another important issue for the firm as well as for the entire industry, is the pace 
of the legalization processes in the recreational segment, both in Europe and the 
rest of the world (excluding the US and Canada, where no major risks are 
expected). Although a positive trend on the sector seems to be expectable, there 
are still several steps and barriers that need to be overcome. 
 
65 Market share was calculated as a proxy based on other markets. It is known that Aurora has around 13% share in 
Canada, and its main investments have been realized in Europe, where it is expected to capture a lower share (later 
assumed to be around 5%). Therefore, in the US, it was considered a share lower than the ones mentioned before, and 
similar for both medical and recreational segments. 
“Another important issue for 
the firm as well as for the 
entire industry, is the pace of 
the legalization processes in 
the recreational segment, both 
in Europe and the rest of the 
world (excluding the US and 
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A base scenario was calculated, where legalizations follow the trends mentioned 
throughout the report. This scenario was attributed a probability of 65% because 
despite being the most probable, it is still unclear how the sector will overcome 
some problems being raised by opposite lobby groups (e.g. moderate international 
institutions like the church, conservative political parties, beverages sector, among 
others). Therefore, a scenario where the growth of the market is not as fast as 
initially planned66 was calculated, giving a share price by DCF of $CAD 2.1 
compared with the $CAD 6.5. of base scenario.  
Valuation Method Legalization Takes Longer Base Scenario Faster Legalization Process 
1. DCF - WACC 2.1 6.5 8.3 
2.1. Multiples EV/ Sales 7.6 7.8 7.9 
2.2. Multiples P/ Sales 9.7 9.9 10.0 
3. Mlt. Past Transact. TV/Sales 9.8 10.1 10.2 
4. APV 2.8 6.8 8.5 
5. FTE 3.7 7.1 8.6 
Figure 29: Scenario analysis on pace of legalizations in Europe and Rest of the World for Recreational Cannabis and its impact on 
Stock price ($CAD) 
A faster legalization process is not likely to happen, and therefore a 5% probability 
was attributed to this scenario, used in order to understand what the implications 















66 In this case, the overall size of the recreational market in those geographies in 2025 was assumed to be around 1/3 of 
the base scenario 
 
 










Income Statement (000´s $CAD) 
Income Statement 2017 2018 2019 2020E 2021E 2022E 2023E 2024E 2025E 
Total Revenue 18.067 55.196 281.097 767.576 1.353.185 1.918.639 2.737.451 3.754.000 4.486.030 
Cost of Sales (7.947) (17.289) (119.743) (266.878) (488.202) (707.385) (1.003.440) (1.385.595) (1.641.881) 
Gross margin 10.120 37.907 161.354 500.698 864.983 1.211.254 1.734.011 2.368.406 2.844.150 
R & D Expenditures (314) (1.679) (14.778) (21.767) (27.767) (31.767) (33.767) (35.767) (36.767) 
Sales/Marketing (10.270) (29.445) (99.289) (230.273) (338.296) (479.660) (547.490) (750.800) (672.905) 
Depreciation & Amortization (716) (12.088) (63.371) (285.393) (365.393) (410.393) (420.393) (430.393) (435.393) 
Professional Fees (1.551)  -   -   -   -   -   -   -   -  
Office, Rent and Administration (6.813) (42.965) (172.365) (272.365) (322.365) (372.365) (377.365) (382.365) (387.365) 
Stock Based Compensation (7.584) (37.450) (107.039) (230.273) (405.955) (575.592) (821.235) (1.126.200) (1.121.508) 
Acquisition costs  -  (15.664) (17.217) (5.811) (2.906) (1.453)  -   -   -  
Operating Margin (17.128) (101.384) (312.705) (545.185) (597.700) (659.976) (466.240) (357.120) 190.212 
Interest income 861 2.514 3.679 7.950  -   -   -   -   -  
Other income  -   -  109.464  -   -   -   -   -   -  
Finance and other costs (6.582) (13.155)  -  15.000 15.000 15.000 15.000 15.000 15.000 
Interest Paid (471) (7.066) (41.025) (96.724) (141.724) (186.724) (231.724) (276.724) (214.483) 
Foreign exchange  (215) (1.038) (3.814) (7.676) (13.532) (19.186) (27.375) (37.540) (44.860) 
Recovery of receivables  -  1.400  -   -   -   -   -   -   -  
Income (loss) before income taxes (23.535) (118.729) (244.401) (626.634) (737.956) (850.886) (710.338) (656.384) (54.131) 
Current tax recovery (expense) 4.296 (8.099) 30.307 97.319 119.788 141.448 127.621 125.918 24.790 
Net income (loss) (19.239) (126.828) (214.094) (529.315) (618.168) (709.438) (582.717) (530.466) (29.341) 
 
Cash Flow Statement (000´s $CAD) 
Cash Flow Reconciliation 2017 2018 2019 2020E 2021E 2022E 2023E 2024E 2025E 
Net Income (8.344) 57.896 (337.062) (529.315) (618.168) (709.438) (582.716) (530.466) (29.341) 
Non-Cash Adjustments 716 12.088 63.371 285.393 365.393 410.393 420.393 430.393 435.393 
Δ Net Working Capital (4.122) (24.501) (70.357) (208.853) (256.531) (333.558) (384.025) (462.342) (562.392) 
Capex Expansion (106.335) (1.432.076) (3.195.546) (1.600.000) (1.000.000) (550.000) (100.000) (100.000) (50.000) 
Maintenance Capex (716) (12.088) (63.371) (285.393) (365.393) (410.393) (420.393) (430.393) (435.393) 
Δ Other Balance Sheet Items (9.112) (103.591) 152.822 25.767 12.884 6.442 3.221 1.610 805 
Δ Non-core items 10.620 6.291 20.479 (18.695) (9.348) (4.674) (2.337) (1.168) (584) 
Total Unlevered Cash Flow (117.293) (1.495.982) (3.429.664) (2.331.096) (1.871.163) (1.591.228) (1.065.857) (1.092.366) (641.511) 
Δ Net Debt (104.022) 209.680 265.686 565.007 300.000 300.000 300.000 300.000 200.000 
Cash Flow to Equity (221.315) (1.286.302) (3.163.978) (1.766.089) (1.571.163) (1.291.228) (765.857) (792.366) (441.511) 
Δ Transactions w/ Shareholders 380.519 1.215.947 3.339.906 1.501.082 1.571.163 1.291.228 765.857 792.366 541.511 
Dividends  -   -   -   -   -   -   -   -   -  
Free Cash Flow 159.204 (70.356) 175.928 (265.007) () () () () 100.000 
Cash BOP 230 159.435 89.079 265.007 () () () () () 
Δ Cash 159.204 (70.356) 175.928 (265.007)  -   -   -   -  100.000 







67 For more detail and years after 2025 please look into the excel file attached 
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Balance Sheet (000´s $CAD) 
Balance sheet 2017 2018 2019 2020E 2021E 2022E 2023E 2024E 2025E 
Assets          
Current          
Cash  159.715 89.193 172.727 15.352 27.064 38.373 54.749 75.080 189.721 
Restricted Cash - - - n/a n/a n/a n/a n/a n/a 
Short term investments 81 990 97.902 n/a n/a n/a n/a n/a n/a 
Accounts receivable 2.312 15.096 103.493 275.634 444.883 630.785 899.984 1.028.493 1.229.049 
Marketable securities 14.845 59.188 143.248 71.624 35.812 17.906 8.953 4.477 2.238 
Biological assets 4.088 13.620 8.833 26.846 49.110 71.158 100.939 139.381 165.162 
Inventory 7.703 29.595 113.641 292.470 468.139 678.314 824.745 1.138.845 1.349.491 
Prepaids  3.126 7.594 24.323 66.417 117.090 166.018 236.868 324.829 388.171 
Total current assets 191.870 215.276 664.167 748.343 1.142.097 1.602.554 2.126.238 2.711.105 3.323.833 
Non-current          
Other Assets 1.736 4.422 6.926 3.463 1.732 866 433 216 108 
PP&E 45.523 246.352 765.567 1.765.567 2.265.567 2.515.567 2.515.567 2.515.567 2.515.567 
Convertible debenture  11.071 - - - - - - - - 
Loans Recceivable - - - - - - - - - 
Derivatives 292 124.942 86.409 43.205 21.602 10.801 5.401 2.700 1.350 
Investment Associat.  - 334.442 118.845 318.845 518.845 618.845 618.845 618.845 618.845 
Intangible assets  31.087 256.232 688.366 1.088.366 1.388.366 1.588.366 1.688.366 1.788.366 1.838.366 
Goodwill 41.100 729.050 3.172.550 3.172.550 3.172.550 3.172.550 3.172.550 3.172.550 3.172.550 
Total non-current assets 130.809 1.695.440 4.838.663 6.391.996 7.368.662 7.906.995 8.001.161 8.098.245 8.146.786 
Total assets 322.679 1.910.716 5.502.830 7.140.339 8.510.759 9.509.549 10.127.400 10.809.350 11.470.619 
Liabilities          
Current          
Accounts payable  8.749 31.162 152.884 365.587 535.016 678.314 824.745 949.037 899.661 
Income taxes payable - 1.659 - - - - - - - 
Deferred revenue 1.421 2.266 749 2.045 3.606 5.112 7.294 10.003 11.953 
Loans and borrowings  69 2.451 13.758 13.758 13.758 13.758 13.758 13.758 13.758 
Derivatives liabilities - - 728 364 182 91 46 23 11 
Accounts Payable PPE 4 16.294 - - - - - - - 
Convertible Debt - - 235.909 235.909 235.909 235.909 235.909 235.909 235.909 
Contingent Considera. 13.221 21.333 32.337 16.169 8.084 4.042 2.021 1.011 505 
Total current liabilitites 23.464 75.165 436.365 633.832 796.555 937.227 1.083.773 1.209.741 1.161.798 
Non-Current          
Convertible Notes  63.536 191.528 267.672 567.672 867.672 1.167.672 1.467.672 1.767.672 2.067.672 
Loans and borrowings  282 9.232 127.486 127.486 127.486 127.486 127.486 127.486 127.486 
Deferred gain  10.206 - 11.979 5.990 2.995 1.497 749 374 187 
Deferred gain deriv. 321 2.254 177.395 88.698 44.349 22.174 11.087 5.544 2.772 
Deferred tax liability 5.937 69.406 91.886 91.886 91.886 91.886 91.886 91.886 91.886 
Total non-current lia. 80.282 272.420 676.418 881.731 1.134.388 1.410.716 1.698.880 1.992.962 2.290.003 
Total liabilities 103.746 347.585 1.112.783 1.515.563 1.930.943 2.347.943 2.782.652 3.202.702 3.451.801 
Shareholders’ equity          
Share capital 221.447 1.466.433 4.673.118 6.153.524 7.726.732 9.017.960 9.783.817 10.576.183 11.017.695 
Reserves 20.745 4.920 139.327 139.327 139.327 139.327 139.327 139.327 139.327 
Accumulated C. Inc. 5.167 (533) (143.170) (672.485) (1.290.653) (2.000.091) (2.582.807) (3.113.273) (3.142.613) 
Retained earnings  (28.426) 87.749 (283.638) n/a n/a n/a n/a n/a n/a 
Non-controlling int. - 4.562 4.410 4.410 4.410 4.410 4.410 4.410 4.410 
Total equity 218.933 1.563.131 4.390.047 5.624.776 6.579.816 7.161.606 7.344.747 7.606.648 8.018.818 
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Disclosures and Disclaimers 
Report Recommendations 
Buy Expected total return (including expected capital gains and expected dividend yield) 
of more than 10% over a 12-month period. 
Hold Expected total return (including expected capital gains and expected dividend yield) 
between 0% and 10% over a 12-month period. 
Sell Expected negative total return (including expected capital gains and expected 
dividend yield) over a 12-month period. 
 
 
This report was prepared by Diogo Moreira and Tomás Portas, two Master in Finance students of Nova School 
of Business and Economics (“Nova SBE”), within the context of the Field Lab – Equity Research. 
This report is issued and published exclusively for academic purposes, namely for academic evaluation and 
master graduation purposes, within the context of said Field Lab – Equity Research. It is not to be construed 
as an offer or a solicitation of an offer to buy or sell any security or financial instrument. 
This report was supervised by a Nova SBE faculty member, acting merely in an academic capacity, who revised 
the valuation methodology and the financial model. 
Given the exclusive academic purpose of the reports produced by Nova SBE students, it is Nova SBE 
understanding that Nova SBE, the author, the present report and its publishing, are excluded from the persons 
and activities requiring previous registration from local regulatory authorities. As such, Nova SBE, its faculty 
and the author of this report have not sought or obtained registration with or certification as financial analyst by 
any local regulator, in any jurisdiction. In Portugal, neither the author of this report nor his/her academic 
supervisor is registered with or qualified under COMISSÃO DO MERCADO DE VALORES MOBILIÁRIOS (“CMVM”, the 
Portuguese Securities Market Authority) as a financial analyst. No approval for publication or distribution of this 
report was required and/or obtained from any local authority, given the exclusive academic nature of the report. 
The additional disclaimers also apply: 
USA: Pursuant to Section 202 (a) (11) of the Investment Advisers Act of 1940, neither Nova SBE nor the author 
of this report are to be qualified as an investment adviser and, thus, registration with the Securities and 
Exchange Commission (“SEC”, United States of America’s securities market authority) is not necessary. 
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Germany: Pursuant to §34c of the WpHG (Wertpapierhandelsgesetz, i.e., the German Securities Trading Act), 
this entity is not required to register with or otherwise notify the Bundesanstalt für Finanzdienstleistungsaufsicht 
(“BaFin”, the German Federal Financial Supervisory Authority). It should be noted that Nova SBE is a fully-
owned state university and there is no relation between the student’s equity reports and any fund-raising 
program. 
UK: Pursuant to section 22 of the Financial Services and Markets Act 2000 (the “FSMA”), for an activity to be 
a regulated activity, it must be carried on “by way of business”. All regulated activities are subject to prior 
authorization by the Financial Conduct Authority (“FCA”). However, this report serves an exclusively academic 
purpose and, as such, was not prepared by way of business. The author - a Master’s student - is the sole and 
exclusive responsible for the information, estimates and forecasts contained herein, and for the opinions 
expressed, which exclusively reflect his/her own judgment at the date of the report. Nova SBE and its faculty 
have no single and formal position in relation to the most appropriate valuation method, estimates or projections 
used in the report and may not be held liable by the author’s choice of the latter. 
The information contained in this report was compiled by students from public sources believed to be reliable, 
but Nova SBE, its faculty, or the students make no representation that it is accurate or complete, and accept 
no liability whatsoever for any direct or indirect loss resulting from the use of this report or of its content. 
Students are free to choose the target companies of the reports. Therefore, Nova SBE may start covering 
and/or suspend the coverage of any listed company, at any time, without prior notice. The students or Nova 
SBE are not responsible for updating this report, and the opinions and recommendations expressed herein may 
change without further notice. 
The target company or security of this report may be simultaneously covered by more than one student. 
Because each student is free to choose the valuation method, and make his/her own assumptions and 
estimates, the resulting projections, price target and recommendations may differ widely, even when referring 
to the same security. Moreover, changing market conditions and/or changing subjective opinions may lead to 
significantly different valuation results. Other students’ opinions, estimates and recommendations, as well as 
the advisor and other faculty members’ opinions may be inconsistent with the views expressed in this report. 
Any recipient of this report should understand that statements regarding future prospects and performance are, 
by nature, subjective, and may be fallible. 
This report does not necessarily mention and/or analyze all possible risks arising from the investment in the 
target company and/or security, namely the possible exchange rate risk resulting from the security being 
denominated in a currency either than the investor’s currency, among many other risks. 
The purpose of publishing this report is merely academic and it is not intended for distribution among private 
investors. The information and opinions expressed in this report are not intended to be available to any person 
other than Portuguese natural or legal persons or persons domiciled in Portugal. While preparing this report, 
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particular needs of any specific person. Investors should seek financial advice regarding the appropriateness 
of investing in any security, namely in the security covered by this report. 
The author hereby certifies that the views expressed in this report accurately reflect his/her personal opinion 
about the target company and its securities. He/ She has not received or been promised any direct or indirect 
compensation for expressing the opinions or recommendation included in this report. 
[If applicable, it shall be added: “While preparing the report, the author may have performed an internship 
(remunerated or not) in [insert the Company’s name]. This Company may have or have had an interest in the 
covered company or security” and/ or “A draft of the reports have been shown to the covered company’s officials 
(Investors Relations Officer or other), mainly for the purpose of correcting inaccuracies, and later modified, prior 
to its publication.”]  
The content of each report has been shown or made public to restricted parties prior to its publication in Nova 
SBE’s website or in Bloomberg Professional, for academic purposes such as its distribution among faculty 
members for students’ academic evaluation. 
Nova SBE is a state-owned university, mainly financed by state subsidies, students tuition fees and companies, 
through donations, or indirectly by hiring educational programs, among other possibilities. Thus, Nova SBE 
may have received compensation from the target company during the last 12 months, related to its fundraising 
programs, or indirectly through the sale of educational, consulting or research services. Nevertheless, no 
compensation eventually received by Nova SBE is in any way related to or dependent on the opinions 
expressed in this report. The Nova School of Business and Economics does not deal for or otherwise offer any 
investment or intermediation services to market counterparties, private or intermediate customers. 
This report may not be reproduced, distributed or published, in whole or in part, without the explicit previous 
consent of its author, unless when used by Nova SBE for academic purposes only. At any time, Nova SBE may 
decide to suspend this report reproduction or distribution without further notice. Neither this document nor any 
copy of it may be taken, transmitted or distributed, directly or indirectly, in any country either than Portugal or 
to any resident outside this country. The dissemination of this document other than in Portugal or to Portuguese 
citizens is therefore prohibited and unlawful. 
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Starting in Canada, the wave of legalizations in Cannabis industry originated several companies. As 
the years passed, more firms started to appear in other geographies with different strategies to face 
the different markets. 
In Europe, Aurora Cannabis, Canopy Growth and Aphria seem to have advantage. In the US, 
Curaleaf, Cronos and Canopy appear in the frontline. And in Canada, Aurora, Canopy, Tilray and 
Aphria seem to be the ones better positioned for the near future. 
Overall, Aurora Cannabis seems to have an advantage in geographical presence but lacks a stronger 




































This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia 
(UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences DataLab, Project 22209), POR 
Lisboa (LISBOA-01-0145-FEDER-007722 and Social Sciences DataLab, Project 22209) and POR 
Norte (Social Sciences DataLab, Project 22209). 
 
 









During the first wave of the cannabis legalization in countries such as Canada, the US, Germany among others, 
major cannabis companies became a hot topic. Likewise, Aurora and its competitors, who rapidly set footprint 
in these markets, saw large increases in revenues. Although “regulation” keeps being the keyword affecting the 
cannabis market and is among one of the major concerns for investors, cannabis players have played different 
strategies in what regards market positioning, channels distributions and productions sites. Therefore, 
understanding the strategies of Aurora’s competitors and businesses can prove to be important to assess the 
firm market share in the foreseeable future, and therefore it was decided to analyze several case studies, in 







Estimated to be worth around $USD 50Bn in 20281, Europe has become an attractive market for major 
Canadian companies. Although only medical cannabis is currently legalized2 in a few countries such as 
Germany, Portugal, Italy among others, most of the strategies deployed by the Canadian companies in this 
market have a long-term view on capturing future market share once further developments are made regarding 
cannabis regulations.  
Starting with Canopy Growth (one of the largest players) which currently has a footprint in seven countries in 
Europe. In Germany, it uses one of the portfolios’ brand called Spectrum Therapeutics, which operates as a 
 
1 Source: Prohibition Partners; Global Cannabis Report; New Frontier Data; Euromonitor; UN ODC 
2 European market is divided in retail and medical. Retail market is consisted of mainly CBD products where THC levels 
are low, whereas medical market consists of cannabis flowers and extracts which are subject to a high scrutiny process 


































Figure 1: European cannabis market and Aurora positioning; Source: Prohibition partners; 
Companies respective annual report 
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pharmaceutical distributor, to legally import from Canada and sell in Europe. More recently, they have acquired 
C3, which is a European cannabinoid-based pharmaceutical company manufacturer and distributor of 
dronabinol3. In Denmark, the same brand, Spectrum Therapeutics, received the necessary licensing to 
cultivate, harvest, export and sell medical cannabis in dried flower form4. In Poland, the company completed 
its first import of medical cannabis into Poland. Even though is not yet legal to sell medical cannabis in Poland, 
it is estimated that up to 300K patients could qualify for medical cannabis5. Likewise, Canopy presents a fair 
competitive advantage in the future medical market in Poland. In Spain, Canopy acquired Cafina, which is one 
of the three companies in Spain legalized to cultivate, distribute and export cannabis containing more than 
0.2% THC for medical and research purposes. In addition, the company entered into a license agreement with 
Alcaliber S.A in FY 2018 whereby Canopy can use certain strains and seeds to be grown and cultivated in 
Alcaliber facilities for sale worldwide. In the United Kingdom in 2019, Spectrum Therapeutics received 
government licenses to store and distribute medical cannabis products from European facilities. Finally, in the 
Czech Republic, Canopy acquired Annabis Medical and they currently import and distribute products through 
pharmacy channels.  
Regarding Tilray, the company is also present in seven countries in the European Union. The international hub 
of the Canadian company is situated in Portugal. In 2017, Tilray was authorized to cultivate, import and export 
bulk medical cannabis form Portugal to the EU and this year was awarded the GMP certification in accordance 
with EMEA standards6. In Germany, the company distributes its products through pharmaceutical wholesalers 
such as Noweda medical cannabis. Lastly, the Canadian company formed partnerships with distributors in 
multiple countries and currently sells its products to the Czech Republic, Croatia, Ireland, United Kingdom, and 
Cyprus through pharmacies distributers.  
Set up in fewer countries in the EU compared to the previously mentioned companies, Aphria has a footprint in 
four countries in Europe. In Germany, the company has a subsidiary called Aphria Deutschland which was 
recently authorized for the cultivation of medical cannabis and could produce around 1,000 kg a year7. Aphria, 
through a partnership with European Flower, is expected to have access to the EU GMP-certified organic 
medical cannabis and have further access to cannabis to sell throughout Europe. In addition, the company 
acquired CC Pharma which is an importer and pharmaceutical distributor for the German market and could 
prove to be helpful to expand the medical cannabis distribution in the German market. In Malta Apria can import 
cannabis for processing, packaging and distribution of EU-GMP certified cannabis products across Europe 
through the subsidiary ASG Pharma8. In Italy, through the subsidiary FL-Group, the firm is authorized to 
 
3 Registered active pharmaceutical ingredient in Germany, Austria, Switzerland and Denmark 
4 Facility which included approximately 300,000 squares feet of licensed greenhouse cultivation.  
5 Source: Canopy Q2 FY2020 report 
6 EU-GMP standards stands for European Union’s Good Manufacturing Practices and is a requirement to sell 
cannabis products in the European market. 
7 After the German government completed a tender process to award licenses for in-country cultivation, the company 
was granted most available lots (5 lots, where 1 lot = 200kg production)  
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distribute its cannabis-based products through pharmacies. Finally, the company also has supply agreements 
for the sale of medical cannabis in the United Kingdom.  
Cronos is a smaller player in the European market with a presence in only two countries. In Germany, the 
company sells medical cannabis products through pharmacies after announcing a five-year exclusive 
distribution agreement with G.Pohl-Boskamp which is an international pharmaceutical manufacturer. Also in 
Poland, the company will distribute within the Polish medical market through a partnership with Delfarma, a 
pharmaceutical wholesaler.  
Aurora Cannabis, with over $CAD 5M in revenue from Europe, has an extensive network distribution that can 
reach up to 15 countries. In Germany, the company acquired Pedanios in 2017, which provided the company 
with a first-mover advantage in the medical market. Aurora was among the first companies to have EU GMP9 
certified facilities which was key to be a pioneer in selling oils in the German market10. In Denmark, the company 
is building a 100-hectare facility in Odense. In Italy, the company signed an agreement whereby they will be 
supplying the Italian government through Aurora Europe for the next two years11. In the rest of the European 
countries, Aurora has either joint ventures or/and allowances to ship medical cannabis and sell exclusively 
through pharmaceutical wholesalers. 
United States  
The United States is currently the largest legal cannabis market, valued around $USD 15Bn despite not having 
federally legalized it for medical or recreational use12. Likewise, most cannabis companies have shown interest 
in the market by unfolding several partnerships and strategies but have also found setbacks given that the 
market is not yet legal at a federal level.  
Curaleaf, an American cannabis producer, distributor, and retailer, which operates only in the US, is currently 
the largest US player after reporting revenues of $USD 176M Year to date. The firm has a presence in 19 
states, particularly in the West Coast (in states such as Oregon, California, Arizona, among others). After 
production and transformation, the company makes their distribution either through their own retail or other 
distribution channels13.  
 
9 Competitors such as Canopy, Cronos, Aphria and Tilray also have EU-GMP certification in some of their facilities 
nowadays. 
10 “Pedanios 5/1” drops were the first extract-derived oil product to be authorized to be sold.  
11 Among the products supplied is usually different types of cannabis strains and medical cannabis flowers (flower high 
in THC, flower with equally THC and CBD and higher CBD flower.  
12 Source: Prohibition Partners; Global Cannabis Report; New Frontier Data;  
13 Products distributed include vape, concentrates, flower, capsules, edibles among others.  
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Canopy formalized an agreement to acquire 100% of Acreage Holdings (the largest multi-state owner of 
cannabis licenses in the US), through a financial option dependent on cannabis legalization at a federal level14. 
A move that would secure market share in the US, since it will give Canopy access to their cultivation and retail 
infrastructure and hence allow the cannabis company to introduce their diverse portfolio of brands such as 
Tweed, Spectrum, Craftgrow among others in the North American country. Although not yet present in the US 
market, further developments in the passage of the Farm Bill15, made the company express their interest to 
enter the US market regarding hemp, as of its last quarterly report.  
Cronos, having Altria16 as a main shareholder, has not yet reported any revenues from the US market. However, 
in September 2019 the company acquired the firm Redwood, which markets and distributes hemp-derived CBD 







In October 2018, Canada became the first country of the G7 to legalize medical cannabis for recreational use. 
Today, the market is worth around $USS 2.5Bn17 and is projected to increase in the upcoming years. For the 
majority of players (including Aurora), Canada is where most of their production capacity is located and is their 
largest source of revenue, having likewise a more complete vertical integrated business than internationally. 
Aurora is currently among the top producers of cannabis with over 700,000kg produced18, revenue leader in 
Canada and among the best cannabis products in 2019. Likewise, revenue leadership alongside low production 
cost is expected to maintain the company market share in the north American country.  
 
14 After paying a premium of nearly $USD 300M Canopy will acquired 100% of Acreage if cannabis turns legal at a 
federal level.  
15 “Agriculture Improvement Act of the United States”, with respect to agricultural and food policy. According to the 
Farm Bill 2018, industrial hemp became legal in the US, bringing the topic back to discussion. 
16 The tobacco company Altria holds a 45% stake in Cronos 
17 Sources: Prohibition Partners; Global Cannabis Report; New Frontier Data; Euromonitor; UN ODC 
18 Source: Aurora annual report; According to each company annual report Canopy capacity = over 500,000kg, Aphria 




Sativa flower Aurora 
Indica flower Aurora 
Hybrid flower Canopy 
Sativa Dominan preroll Aphria 
Indica Dominant preroll Aphria 
Hybrid preroll Aphria 
High CBD bottle oil Aphria 
Balanced bottled oil Aurora 
Cannabis spray Aurora 
Cannabis capsules Canopy 
Figure 2: 2019 Canadian revenue breakdown by company - Source: 
Company respective annual report - Note: Cost of grams sold consists of 
Total sales divided by kilograms sold 
Figure 3: Canadian cannabis awards; 
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Figure 4: Aurora vs Competitors - Source: Companies respective annual reports - Cronos, Hexo and Curaleaf were not included due 
to lack of information 
To conclude, overall Aurora has a fair competitive advantage in what regards production and geographical 
reach. Moreover, the new laws in countries in the EU, such as UK and Poland, allowing for the import of 
cannabis, will prove to be important to continue among the largest cannabis sellers in the EU. Also, by supplying 
the Italian market and producing in Germany19,which are expected to be the largest cannabis markets in 
Europe, Aurora presents a critical first-move advantage compared to most of its peers. Nonetheless, one strong 
competitor Aurora might face for the next quarters regarding the EU market, is Aphria which is present in the 
largest markets in Europe alongside strong distributions channels.  
 
On the other hand, the company has a disadvantage regarding the United States market which is forecasted 
to be one of the largest markets worldwide. The market share leader in the US is Curaleaf, however that does 
not mean they will not face competition over the next quarters. As soon as the United States legalizes cannabis, 
companies such as Cronos and Canopy can quickly leverage their production and distribution across the 
country20. Until the market in the US becomes legal, the probability of Aurora turning its investment to the US 
is low given the company is focusing on the European market where it holds competitive advantage against its 
peers. Therefore, there is a low probability of Aurora becoming market share leader in the US cannabis market 
in the next quarters. 
 
 
19 Source: Prohibition partners 
20 Given the strong shareholders reputation such as Constellation brands and Altria, the two Canadian companies have 
easier access to the distribution network across the US 
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